tiprankstipranks
Allogene Therapeutics’ Stability Threatened by Banking Sector Turmoil
PremiumCompany AnnouncementsAllogene Therapeutics’ Stability Threatened by Banking Sector Turmoil
1M ago
JPMorgan biotech/pharma analysts hold an analyst/industry conference call
PremiumThe Fly
JPMorgan biotech/pharma analysts hold an analyst/industry conference call
1M ago
Allogene Therapeutics files $500M mixed securities shelf
PremiumThe Fly
Allogene Therapeutics files $500M mixed securities shelf
1M ago
Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Disease
PremiumPress ReleasesAllogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Disease
1M ago
Allogene Therapeutics management to meet with Truist
PremiumThe Fly
Allogene Therapeutics management to meet with Truist
1M ago
Allogene Therapeutics management to meet with Truist
PremiumThe Fly
Allogene Therapeutics management to meet with Truist
1M ago
Allogene Therapeutics to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments Related to the December 2020 Formation of the Allogene Overland Biopharm Joint Venture in Asia
PremiumPress ReleasesAllogene Therapeutics to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments Related to the December 2020 Formation of the Allogene Overland Biopharm Joint Venture in Asia
2M ago
Allogene Therapeutics to restate previously filed financial statements
PremiumThe Fly
Allogene Therapeutics to restate previously filed financial statements
2M ago
Allogene Therapeutics price target lowered to $10 from $12 at H.C. Wainwright
PremiumThe Fly
Allogene Therapeutics price target lowered to $10 from $12 at H.C. Wainwright
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100